Arbutus Biopharma CORP Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Whitefort Capital Master Fund has adjusted its position in Arbutus Biopharma, reaching an 8.0% beneficial ownership stake and 9.8% total economic exposure.
NASDAQ
Whitefort Capital Master Fund, LP has significantly increased its holdings in Arbutus Biopharma Corp, acquiring over 15.7 million shares in the past 60 days.
NASDAQ
SCHEDULE 13D/A: Roivant Sciences Orchestrates Major Board Overhaul at Arbutus Biopharma, Appointing New CEO and Directors
Roivant Sciences Ltd., a significant shareholder in Arbutus Biopharma Corp, has successfully orchestrated a complete change in Arbutus's Board of Directors, reducing its size and appointing new leadership, including a new CEO.
NASDAQ
SCHEDULE 13D/A: Whitefort Capital Boosts Arbutus Biopharma Stake to 7% and Signals Intent for Board Changes
Whitefort Capital Master Fund, LP has increased its beneficial ownership in Arbutus Biopharma Corp to 7.0% and plans to engage with the company and shareholders to drive value, including potential changes to the Board of Directors.
NASDAQ
SCHEDULE 13D/A: Roivant Sciences Amends Arbutus Biopharma Stake, Signals Potential Board and Management Changes
Roivant Sciences Ltd. has filed an Amendment No. 12 to its Schedule 13D, reaffirming its 20.5% beneficial ownership in Arbutus Biopharma Corp. and indicating potential near-term changes to the Issuer's board of directors and management.